Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer

Abstract

The recommended dose of S-1 with concurrent radiotherapy was determined to be 80 mg/m(2)/day from Day 1 to 14 and 22 to 35 in patients with locally advanced pancreatic cancer. Oral S-1 and radiotherapy is well tolerated and feasible and should be further investigated.

Clinical Results of Radiotherapy for Locally Advanced Stage III Pancreatic Cancer: A Single Institutional Experience

“…The median survival time of the patients with locally advanced pancreatic cancers that received chemoradiotherapy or radiotherapy alone or chemotherapy alone was found to be between 5.7-16.8 in a previous randomized controlled study [8][9][10][12][13][14][15][16]. In particular, the results of the median survival time with chemoradiotherapy with TS-1 had been 11-16.8 months [17][18][19][20][21][22]. Our study included 12 patients with TS-1 and a median survival time of 10.8 months, which is slightly inferior compared to previous reports.…”

Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan

“…This agent has been extensively evaluated for the treatment of locally advanced disease, and several phase I studies of S-1 combined with radiotherapy have been conducted in Japan. [20][21][22] A multi-institutional phase II trial of this combination therapy is now underway.…”

Phase II Study of Preoperative Concurrent Chemoradiation Therapy With S-1 in Patients With T4 Oral Squamous Cell Carcinoma

“…In patients with various cancers, including head-and-neck cancer, S-1 administered alone or in combination with other chemotherapeutic agents achieved promising results (15)(16)(17)(18). Both tegafur and gimeracil in S-1 have been suggested to have radiosensitizing properties (19)(20)(21). The advantages of CCRT with S-1 have been investigated in patients with head-and-neck, lung, rectal, and pancreatic cancer (21)(22)(23)(24).…”

“…Both tegafur and gimeracil in S-1 have been suggested to have radiosensitizing properties (19)(20)(21). The advantages of CCRT with S-1 have been investigated in patients with head-and-neck, lung, rectal, and pancreatic cancer (21)(22)(23)(24).…”